Investigational drug · Phase 2
COH04S1
Also called: GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "COH04S1"
First trial start
2020
Nov 19, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "COH04S1", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19 Infection
- Hematopoietic and Lymphoid System Neoplasm
- Leukemia
- Lymphoma
- Plasma Cell Myeloma
Approved drugs for the same conditions: COVID-19 · Oncology · Hematology and blood cancers · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "COH04S1" as an intervention, largest first.
- A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 InfectionPivotal-lookingCompleted
GeoVax, Inc.Industry
NCT04639466 · 119 participants · Start Nov 19, 2020 · Primary completion Oct 31, 2025
Drug: Placebo Administration; Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 · For: COVID-19 Infection
Sites: Claremont, California; Duarte, California; Thousand Oaks, California
- SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood CancerActive, not recruiting
GeoVax, Inc.Industry
NCT04977024 · 63 participants · Start Sep 27, 2021 · Primary completion Dec 31, 2026
Drug: COVID-19 Vaccine; Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 · For: COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia and 2 more
Sites: Duarte, California; Baltimore, Maryland; Worcester, Massachusetts · 6 sites in all
City of Hope Medical CenterAcademic, hospital or other
NCT05672355 · 47 participants · Start Aug 1, 2023 · Primary completion Jun 29, 2026
Drug: mRNA COVID-19 Vaccine; Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 · For: Chronic Lymphocytic Leukemia; COVID-19 Infection
Sites: Duarte, California
Newest research
PubMed records naming it or its code names, newest first.
- Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity.
Ortega-Francisco S, Prudente de Aquino MT, Chiuppesi F, et al. · J Infect 2026
- Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.
Ortega-Francisco S, Prudente de Aquino MT, La Rosa C, et al. · Br J Haematol 2026
- Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.
Elsharkawy A, Stone S, Guglani A, et al. · Front Immunol 2025
- Exploring co-infection dynamics and immune response interactions between COVID-19 and Monkeypox: implications for disease severity, viral transmission, and vaccine efficacy.
Ayo-Farai O, Gopep N, Alarape-Raji A, et al. · Virol J 2025
- Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
Chiuppesi F, Zaia JA, Gutierrez-Franco MA, et al. · Commun Med (Lond) 2024
- Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
Chiuppesi F, Ortega-Francisco S, Gutierrez MA, et al. · Vaccines (Basel) 2023
Also in development for COVID-19 Infection
- ibuzatrelvirPF-07817883Phase 32 trials
Pfizer · COVID-19 SARS-CoV-2 Infection, COVID-19 Infection
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.